1,233 results on '"A. Man"'
Search Results
2. Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation
3. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world
4. Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels
5. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B
6. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe
7. Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis
8. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis
9. Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)
10. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion
11. Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma
12. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
13. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials
14. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
15. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss
16. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma
17. WED-373-YI Epidemiological data and clinical profiles of hepatitis B surface antigen levels in chronic hepatitis B: implications for novel drug development
18. FRI-473 The oncogenic m6A demethylase FTO promotes tumorigenesis and immune escape by upregulating GPNMB in hepatocellular carcinoma
19. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
20. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
21. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
22. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
23. Chronic hepatitis E: Advancing research and patient care
24. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
25. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
26. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma
27. Outcomes of living liver donors are worse than those of matched healthy controls
28. LBP-019 Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B
29. FRI-132 Spontaneous bacterial empyema is a rare yet life-threatening complication in patients with hepatic hydrothorax
30. OS-032 Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989
31. SAT-474 Lesions hyper- to isointense to the surrounding liver in the hepatobiliary phase of gadoxetic acid enhanced MRI
32. WED-361 Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels
33. THU-078 Extra-hepatic organ failure in ACLF patients is associated with poor survival and limited curative therapy-results from AARC cohort
34. THU-258-YI Altered liver vascular biology occurring in early stages of metabolic dysfunction-associated steatotic liver disease is significantly improved by the pan-peroxisome proliferatoractivated receptoragonist lanifibranor, associating with improved liver histology
35. WED-376 Tobevibart (VIR-3434), a monoclonal antibody, resistance analysis in participants with chronic HBV: Results from a Phase 1 single dose study
36. THU-249 The role of the ferroptosis brake glutathione peroxidase 4 in a preclinical model of metabolic dysfunction-associated steatohepatitis
37. THU-052 Therapeutic plasma-exchange improves short-term survival in patients with ACLF admitted to intensive care unit with organ failures-a multinational AARC data analysis
38. SAT-314 Impact of hepatic steatosis on risk of acute liver injury among people with chronic hepatitis B and SARS-CoV-2 infection
39. WED-198 Novel deep learning models utilising domain adaptation outperform conventional statistical models for predicting the risk of liver-related complications in patients with metabolic dysfunction-associated steatotic liver disease
40. FRI-490-YI Intratumoural microbiome alterations predict postoperative recurrence and mortality in hepatocellular carcinoma after hepatic resection
41. LBP-001 Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study
42. OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
43. WED-375 VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels
44. SAT-392 Perturbed pathways of lipid metabolism in patients with chronic hepatitis B infection after cessation of long term nucleos (t)ide analogue
45. FRI-388 Clinically significant liver stiffness decrease, as defined by the Baveno VII consensus, is associated with improved long-term prognosis in chronic hepatitis B patients with compensated advanced chronic liver disease
46. SAT-375 Proteomic analysis of plasma exosomes: a novel method to identify potential therapeutic targets for chronic hepatitis B
47. SAT-337 Serum levels of IgA inform on the transcriptomic architecture of the liver and predict hepatocellular carcinoma in chronic viral hepatitis patients
48. WED-367 Viral sequence analysis of chronic hepatitis B (CHB) patients treated with the silencing RNA (siRNA) JNJ-3989 in the REEF-1 and REEF-2 clinical studies
49. WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
50. TOP-401-YI Improvement of liver stiffness during nucleo (s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.